Home Healthcare Pharmaceuticals Clot Busting Drugs Market

Clot Busting Drugs Market Size, Share & Trends Analysis Report By Drug Class (Tissue Plasminogen Activators, Streptokinase, Urokinase, Other Thrombolytic Drugs), By Indication (Acute Ischemic Stroke, Acute Myocardial Infarction, Pulmonary Embolism, Deep Vein Thrombosis), By Route of Administration (Intravenous, Intracoronary, Intra-Arterial, Catheter-Directed Administration), By End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Other End Users) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Last Updated: October 19, 2026 | Author: Debashree Bora | Format:
Overview TOC Segmentation Methodology
Download Free Sample

Market Segmentation

  1. Clot Busting Drugs Market, By Drug Class 2025-2034 (USD MILLION/ Units)
    1. Tissue Plasminogen Activators
    2. Streptokinase
    3. Urokinase
    4. Other Thrombolytic Drugs
  2. Clot Busting Drugs Market, By Indication 2025-2034 (USD MILLION/ Units)
    1. Acute Ischemic Stroke
    2. Acute Myocardial Infarction
    3. Pulmonary Embolism
    4. Deep Vein Thrombosis
  3. Clot Busting Drugs Market, By Route of Administration 2025-2034 (USD MILLION/ Units)
    1. Intravenous
    2. Intracoronary
    3. Intra-Arterial
    4. Catheter-Directed Administration
  4. Clot Busting Drugs Market, By End User 2025-2034 (USD MILLION/ Units)
    1. Hospitals
    2. Specialty Clinics
    3. Ambulatory Surgical Centers
    4. Other End Users
  5. Regional Clot Busting Drugs Market
    1. North America
      1. North America Clot Busting Drugs Market By Drug Class 2025-2034 (USD MILLION/ Units)
        1. Tissue Plasminogen Activators
        2. Streptokinase
        3. Urokinase
        4. Other Thrombolytic Drugs
      2. North America Clot Busting Drugs Market By Indication 2025-2034 (USD MILLION/ Units)
        1. Acute Ischemic Stroke
        2. Acute Myocardial Infarction
        3. Pulmonary Embolism
        4. Deep Vein Thrombosis
      3. North America Clot Busting Drugs Market By Route of Administration 2025-2034 (USD MILLION/ Units)
        1. Intravenous
        2. Intracoronary
        3. Intra-Arterial
        4. Catheter-Directed Administration
      4. North America Clot Busting Drugs Market By End User 2025-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Specialty Clinics
        3. Ambulatory Surgical Centers
        4. Other End Users
      5. U.S.
        1. Tissue Plasminogen Activators
        2. Streptokinase
        3. Urokinase
        4. Other Thrombolytic Drugs
        5. Acute Ischemic Stroke
        6. Acute Myocardial Infarction
        7. Pulmonary Embolism
        8. Deep Vein Thrombosis
        9. Intravenous
        10. Intracoronary
        11. Intra-Arterial
        12. Catheter-Directed Administration
        13. Hospitals
        14. Specialty Clinics
        15. Ambulatory Surgical Centers
        16. Other End Users
      6. Canada
        1. Tissue Plasminogen Activators
        2. Streptokinase
        3. Urokinase
        4. Other Thrombolytic Drugs
        5. Acute Ischemic Stroke
        6. Acute Myocardial Infarction
        7. Pulmonary Embolism
        8. Deep Vein Thrombosis
        9. Intravenous
        10. Intracoronary
        11. Intra-Arterial
        12. Catheter-Directed Administration
        13. Hospitals
        14. Specialty Clinics
        15. Ambulatory Surgical Centers
        16. Other End Users
    2. Europe
      1. Europe Clot Busting Drugs Market By Drug Class 2025-2034 (USD MILLION/ Units)
        1. Tissue Plasminogen Activators
        2. Streptokinase
        3. Urokinase
        4. Other Thrombolytic Drugs
      2. Europe Clot Busting Drugs Market By Indication 2025-2034 (USD MILLION/ Units)
        1. Acute Ischemic Stroke
        2. Acute Myocardial Infarction
        3. Pulmonary Embolism
        4. Deep Vein Thrombosis
      3. Europe Clot Busting Drugs Market By Route of Administration 2025-2034 (USD MILLION/ Units)
        1. Intravenous
        2. Intracoronary
        3. Intra-Arterial
        4. Catheter-Directed Administration
      4. Europe Clot Busting Drugs Market By End User 2025-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Specialty Clinics
        3. Ambulatory Surgical Centers
        4. Other End Users
      5. U.K.
        1. Tissue Plasminogen Activators
        2. Streptokinase
        3. Urokinase
        4. Other Thrombolytic Drugs
        5. Acute Ischemic Stroke
        6. Acute Myocardial Infarction
        7. Pulmonary Embolism
        8. Deep Vein Thrombosis
        9. Intravenous
        10. Intracoronary
        11. Intra-Arterial
        12. Catheter-Directed Administration
        13. Hospitals
        14. Specialty Clinics
        15. Ambulatory Surgical Centers
        16. Other End Users
      6. Germany
        1. Tissue Plasminogen Activators
        2. Streptokinase
        3. Urokinase
        4. Other Thrombolytic Drugs
        5. Acute Ischemic Stroke
        6. Acute Myocardial Infarction
        7. Pulmonary Embolism
        8. Deep Vein Thrombosis
        9. Intravenous
        10. Intracoronary
        11. Intra-Arterial
        12. Catheter-Directed Administration
        13. Hospitals
        14. Specialty Clinics
        15. Ambulatory Surgical Centers
        16. Other End Users
      7. France
        1. Tissue Plasminogen Activators
        2. Streptokinase
        3. Urokinase
        4. Other Thrombolytic Drugs
        5. Acute Ischemic Stroke
        6. Acute Myocardial Infarction
        7. Pulmonary Embolism
        8. Deep Vein Thrombosis
        9. Intravenous
        10. Intracoronary
        11. Intra-Arterial
        12. Catheter-Directed Administration
        13. Hospitals
        14. Specialty Clinics
        15. Ambulatory Surgical Centers
        16. Other End Users
      8. Spain
        1. Tissue Plasminogen Activators
        2. Streptokinase
        3. Urokinase
        4. Other Thrombolytic Drugs
        5. Acute Ischemic Stroke
        6. Acute Myocardial Infarction
        7. Pulmonary Embolism
        8. Deep Vein Thrombosis
        9. Intravenous
        10. Intracoronary
        11. Intra-Arterial
        12. Catheter-Directed Administration
        13. Hospitals
        14. Specialty Clinics
        15. Ambulatory Surgical Centers
        16. Other End Users
      9. Italy
        1. Tissue Plasminogen Activators
        2. Streptokinase
        3. Urokinase
        4. Other Thrombolytic Drugs
        5. Acute Ischemic Stroke
        6. Acute Myocardial Infarction
        7. Pulmonary Embolism
        8. Deep Vein Thrombosis
        9. Intravenous
        10. Intracoronary
        11. Intra-Arterial
        12. Catheter-Directed Administration
        13. Hospitals
        14. Specialty Clinics
        15. Ambulatory Surgical Centers
        16. Other End Users
      10. Russia
        1. Tissue Plasminogen Activators
        2. Streptokinase
        3. Urokinase
        4. Other Thrombolytic Drugs
        5. Acute Ischemic Stroke
        6. Acute Myocardial Infarction
        7. Pulmonary Embolism
        8. Deep Vein Thrombosis
        9. Intravenous
        10. Intracoronary
        11. Intra-Arterial
        12. Catheter-Directed Administration
        13. Hospitals
        14. Specialty Clinics
        15. Ambulatory Surgical Centers
        16. Other End Users
      11. Nordic
        1. Tissue Plasminogen Activators
        2. Streptokinase
        3. Urokinase
        4. Other Thrombolytic Drugs
        5. Acute Ischemic Stroke
        6. Acute Myocardial Infarction
        7. Pulmonary Embolism
        8. Deep Vein Thrombosis
        9. Intravenous
        10. Intracoronary
        11. Intra-Arterial
        12. Catheter-Directed Administration
        13. Hospitals
        14. Specialty Clinics
        15. Ambulatory Surgical Centers
        16. Other End Users
      12. Benelux
        1. Tissue Plasminogen Activators
        2. Streptokinase
        3. Urokinase
        4. Other Thrombolytic Drugs
        5. Acute Ischemic Stroke
        6. Acute Myocardial Infarction
        7. Pulmonary Embolism
        8. Deep Vein Thrombosis
        9. Intravenous
        10. Intracoronary
        11. Intra-Arterial
        12. Catheter-Directed Administration
        13. Hospitals
        14. Specialty Clinics
        15. Ambulatory Surgical Centers
        16. Other End Users
      13. Rest of Europe
        1. Tissue Plasminogen Activators
        2. Streptokinase
        3. Urokinase
        4. Other Thrombolytic Drugs
        5. Acute Ischemic Stroke
        6. Acute Myocardial Infarction
        7. Pulmonary Embolism
        8. Deep Vein Thrombosis
        9. Intravenous
        10. Intracoronary
        11. Intra-Arterial
        12. Catheter-Directed Administration
        13. Hospitals
        14. Specialty Clinics
        15. Ambulatory Surgical Centers
        16. Other End Users
    3. APAC
      1. APAC Clot Busting Drugs Market By Drug Class 2025-2034 (USD MILLION/ Units)
        1. Tissue Plasminogen Activators
        2. Streptokinase
        3. Urokinase
        4. Other Thrombolytic Drugs
      2. APAC Clot Busting Drugs Market By Indication 2025-2034 (USD MILLION/ Units)
        1. Acute Ischemic Stroke
        2. Acute Myocardial Infarction
        3. Pulmonary Embolism
        4. Deep Vein Thrombosis
      3. APAC Clot Busting Drugs Market By Route of Administration 2025-2034 (USD MILLION/ Units)
        1. Intravenous
        2. Intracoronary
        3. Intra-Arterial
        4. Catheter-Directed Administration
      4. APAC Clot Busting Drugs Market By End User 2025-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Specialty Clinics
        3. Ambulatory Surgical Centers
        4. Other End Users
      5. China
        1. Tissue Plasminogen Activators
        2. Streptokinase
        3. Urokinase
        4. Other Thrombolytic Drugs
        5. Acute Ischemic Stroke
        6. Acute Myocardial Infarction
        7. Pulmonary Embolism
        8. Deep Vein Thrombosis
        9. Intravenous
        10. Intracoronary
        11. Intra-Arterial
        12. Catheter-Directed Administration
        13. Hospitals
        14. Specialty Clinics
        15. Ambulatory Surgical Centers
        16. Other End Users
      6. Korea
        1. Tissue Plasminogen Activators
        2. Streptokinase
        3. Urokinase
        4. Other Thrombolytic Drugs
        5. Acute Ischemic Stroke
        6. Acute Myocardial Infarction
        7. Pulmonary Embolism
        8. Deep Vein Thrombosis
        9. Intravenous
        10. Intracoronary
        11. Intra-Arterial
        12. Catheter-Directed Administration
        13. Hospitals
        14. Specialty Clinics
        15. Ambulatory Surgical Centers
        16. Other End Users
      7. Japan
        1. Tissue Plasminogen Activators
        2. Streptokinase
        3. Urokinase
        4. Other Thrombolytic Drugs
        5. Acute Ischemic Stroke
        6. Acute Myocardial Infarction
        7. Pulmonary Embolism
        8. Deep Vein Thrombosis
        9. Intravenous
        10. Intracoronary
        11. Intra-Arterial
        12. Catheter-Directed Administration
        13. Hospitals
        14. Specialty Clinics
        15. Ambulatory Surgical Centers
        16. Other End Users
      8. India
        1. Tissue Plasminogen Activators
        2. Streptokinase
        3. Urokinase
        4. Other Thrombolytic Drugs
        5. Acute Ischemic Stroke
        6. Acute Myocardial Infarction
        7. Pulmonary Embolism
        8. Deep Vein Thrombosis
        9. Intravenous
        10. Intracoronary
        11. Intra-Arterial
        12. Catheter-Directed Administration
        13. Hospitals
        14. Specialty Clinics
        15. Ambulatory Surgical Centers
        16. Other End Users
      9. Australia
        1. Tissue Plasminogen Activators
        2. Streptokinase
        3. Urokinase
        4. Other Thrombolytic Drugs
        5. Acute Ischemic Stroke
        6. Acute Myocardial Infarction
        7. Pulmonary Embolism
        8. Deep Vein Thrombosis
        9. Intravenous
        10. Intracoronary
        11. Intra-Arterial
        12. Catheter-Directed Administration
        13. Hospitals
        14. Specialty Clinics
        15. Ambulatory Surgical Centers
        16. Other End Users
      10. Taiwan
        1. Tissue Plasminogen Activators
        2. Streptokinase
        3. Urokinase
        4. Other Thrombolytic Drugs
        5. Acute Ischemic Stroke
        6. Acute Myocardial Infarction
        7. Pulmonary Embolism
        8. Deep Vein Thrombosis
        9. Intravenous
        10. Intracoronary
        11. Intra-Arterial
        12. Catheter-Directed Administration
        13. Hospitals
        14. Specialty Clinics
        15. Ambulatory Surgical Centers
        16. Other End Users
      11. South East Asia
        1. Tissue Plasminogen Activators
        2. Streptokinase
        3. Urokinase
        4. Other Thrombolytic Drugs
        5. Acute Ischemic Stroke
        6. Acute Myocardial Infarction
        7. Pulmonary Embolism
        8. Deep Vein Thrombosis
        9. Intravenous
        10. Intracoronary
        11. Intra-Arterial
        12. Catheter-Directed Administration
        13. Hospitals
        14. Specialty Clinics
        15. Ambulatory Surgical Centers
        16. Other End Users
      12. Rest of Asia-Pacific
        1. Tissue Plasminogen Activators
        2. Streptokinase
        3. Urokinase
        4. Other Thrombolytic Drugs
        5. Acute Ischemic Stroke
        6. Acute Myocardial Infarction
        7. Pulmonary Embolism
        8. Deep Vein Thrombosis
        9. Intravenous
        10. Intracoronary
        11. Intra-Arterial
        12. Catheter-Directed Administration
        13. Hospitals
        14. Specialty Clinics
        15. Ambulatory Surgical Centers
        16. Other End Users
    4. Middle East and Africa
      1. Middle East and Africa Clot Busting Drugs Market By Drug Class 2025-2034 (USD MILLION/ Units)
        1. Tissue Plasminogen Activators
        2. Streptokinase
        3. Urokinase
        4. Other Thrombolytic Drugs
      2. Middle East and Africa Clot Busting Drugs Market By Indication 2025-2034 (USD MILLION/ Units)
        1. Acute Ischemic Stroke
        2. Acute Myocardial Infarction
        3. Pulmonary Embolism
        4. Deep Vein Thrombosis
      3. Middle East and Africa Clot Busting Drugs Market By Route of Administration 2025-2034 (USD MILLION/ Units)
        1. Intravenous
        2. Intracoronary
        3. Intra-Arterial
        4. Catheter-Directed Administration
      4. Middle East and Africa Clot Busting Drugs Market By End User 2025-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Specialty Clinics
        3. Ambulatory Surgical Centers
        4. Other End Users
      5. UAE
        1. Tissue Plasminogen Activators
        2. Streptokinase
        3. Urokinase
        4. Other Thrombolytic Drugs
        5. Acute Ischemic Stroke
        6. Acute Myocardial Infarction
        7. Pulmonary Embolism
        8. Deep Vein Thrombosis
        9. Intravenous
        10. Intracoronary
        11. Intra-Arterial
        12. Catheter-Directed Administration
        13. Hospitals
        14. Specialty Clinics
        15. Ambulatory Surgical Centers
        16. Other End Users
      6. Turkey
        1. Tissue Plasminogen Activators
        2. Streptokinase
        3. Urokinase
        4. Other Thrombolytic Drugs
        5. Acute Ischemic Stroke
        6. Acute Myocardial Infarction
        7. Pulmonary Embolism
        8. Deep Vein Thrombosis
        9. Intravenous
        10. Intracoronary
        11. Intra-Arterial
        12. Catheter-Directed Administration
        13. Hospitals
        14. Specialty Clinics
        15. Ambulatory Surgical Centers
        16. Other End Users
      7. Saudi Arabia
        1. Tissue Plasminogen Activators
        2. Streptokinase
        3. Urokinase
        4. Other Thrombolytic Drugs
        5. Acute Ischemic Stroke
        6. Acute Myocardial Infarction
        7. Pulmonary Embolism
        8. Deep Vein Thrombosis
        9. Intravenous
        10. Intracoronary
        11. Intra-Arterial
        12. Catheter-Directed Administration
        13. Hospitals
        14. Specialty Clinics
        15. Ambulatory Surgical Centers
        16. Other End Users
      8. South Africa
        1. Tissue Plasminogen Activators
        2. Streptokinase
        3. Urokinase
        4. Other Thrombolytic Drugs
        5. Acute Ischemic Stroke
        6. Acute Myocardial Infarction
        7. Pulmonary Embolism
        8. Deep Vein Thrombosis
        9. Intravenous
        10. Intracoronary
        11. Intra-Arterial
        12. Catheter-Directed Administration
        13. Hospitals
        14. Specialty Clinics
        15. Ambulatory Surgical Centers
        16. Other End Users
      9. Egypt
        1. Tissue Plasminogen Activators
        2. Streptokinase
        3. Urokinase
        4. Other Thrombolytic Drugs
        5. Acute Ischemic Stroke
        6. Acute Myocardial Infarction
        7. Pulmonary Embolism
        8. Deep Vein Thrombosis
        9. Intravenous
        10. Intracoronary
        11. Intra-Arterial
        12. Catheter-Directed Administration
        13. Hospitals
        14. Specialty Clinics
        15. Ambulatory Surgical Centers
        16. Other End Users
      10. Nigeria
        1. Tissue Plasminogen Activators
        2. Streptokinase
        3. Urokinase
        4. Other Thrombolytic Drugs
        5. Acute Ischemic Stroke
        6. Acute Myocardial Infarction
        7. Pulmonary Embolism
        8. Deep Vein Thrombosis
        9. Intravenous
        10. Intracoronary
        11. Intra-Arterial
        12. Catheter-Directed Administration
        13. Hospitals
        14. Specialty Clinics
        15. Ambulatory Surgical Centers
        16. Other End Users
      11. Rest of MEA
        1. Tissue Plasminogen Activators
        2. Streptokinase
        3. Urokinase
        4. Other Thrombolytic Drugs
        5. Acute Ischemic Stroke
        6. Acute Myocardial Infarction
        7. Pulmonary Embolism
        8. Deep Vein Thrombosis
        9. Intravenous
        10. Intracoronary
        11. Intra-Arterial
        12. Catheter-Directed Administration
        13. Hospitals
        14. Specialty Clinics
        15. Ambulatory Surgical Centers
        16. Other End Users
    5. LATAM
      1. LATAM Clot Busting Drugs Market By Drug Class 2025-2034 (USD MILLION/ Units)
        1. Tissue Plasminogen Activators
        2. Streptokinase
        3. Urokinase
        4. Other Thrombolytic Drugs
      2. LATAM Clot Busting Drugs Market By Indication 2025-2034 (USD MILLION/ Units)
        1. Acute Ischemic Stroke
        2. Acute Myocardial Infarction
        3. Pulmonary Embolism
        4. Deep Vein Thrombosis
      3. LATAM Clot Busting Drugs Market By Route of Administration 2025-2034 (USD MILLION/ Units)
        1. Intravenous
        2. Intracoronary
        3. Intra-Arterial
        4. Catheter-Directed Administration
      4. LATAM Clot Busting Drugs Market By End User 2025-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Specialty Clinics
        3. Ambulatory Surgical Centers
        4. Other End Users
      5. Brazil
        1. Tissue Plasminogen Activators
        2. Streptokinase
        3. Urokinase
        4. Other Thrombolytic Drugs
        5. Acute Ischemic Stroke
        6. Acute Myocardial Infarction
        7. Pulmonary Embolism
        8. Deep Vein Thrombosis
        9. Intravenous
        10. Intracoronary
        11. Intra-Arterial
        12. Catheter-Directed Administration
        13. Hospitals
        14. Specialty Clinics
        15. Ambulatory Surgical Centers
        16. Other End Users
      6. Mexico
        1. Tissue Plasminogen Activators
        2. Streptokinase
        3. Urokinase
        4. Other Thrombolytic Drugs
        5. Acute Ischemic Stroke
        6. Acute Myocardial Infarction
        7. Pulmonary Embolism
        8. Deep Vein Thrombosis
        9. Intravenous
        10. Intracoronary
        11. Intra-Arterial
        12. Catheter-Directed Administration
        13. Hospitals
        14. Specialty Clinics
        15. Ambulatory Surgical Centers
        16. Other End Users
      7. Argentina
        1. Tissue Plasminogen Activators
        2. Streptokinase
        3. Urokinase
        4. Other Thrombolytic Drugs
        5. Acute Ischemic Stroke
        6. Acute Myocardial Infarction
        7. Pulmonary Embolism
        8. Deep Vein Thrombosis
        9. Intravenous
        10. Intracoronary
        11. Intra-Arterial
        12. Catheter-Directed Administration
        13. Hospitals
        14. Specialty Clinics
        15. Ambulatory Surgical Centers
        16. Other End Users
      8. Chile
        1. Tissue Plasminogen Activators
        2. Streptokinase
        3. Urokinase
        4. Other Thrombolytic Drugs
        5. Acute Ischemic Stroke
        6. Acute Myocardial Infarction
        7. Pulmonary Embolism
        8. Deep Vein Thrombosis
        9. Intravenous
        10. Intracoronary
        11. Intra-Arterial
        12. Catheter-Directed Administration
        13. Hospitals
        14. Specialty Clinics
        15. Ambulatory Surgical Centers
        16. Other End Users
      9. Colombia
        1. Tissue Plasminogen Activators
        2. Streptokinase
        3. Urokinase
        4. Other Thrombolytic Drugs
        5. Acute Ischemic Stroke
        6. Acute Myocardial Infarction
        7. Pulmonary Embolism
        8. Deep Vein Thrombosis
        9. Intravenous
        10. Intracoronary
        11. Intra-Arterial
        12. Catheter-Directed Administration
        13. Hospitals
        14. Specialty Clinics
        15. Ambulatory Surgical Centers
        16. Other End Users
      10. Rest of LATAM
        1. Tissue Plasminogen Activators
        2. Streptokinase
        3. Urokinase
        4. Other Thrombolytic Drugs
        5. Acute Ischemic Stroke
        6. Acute Myocardial Infarction
        7. Pulmonary Embolism
        8. Deep Vein Thrombosis
        9. Intravenous
        10. Intracoronary
        11. Intra-Arterial
        12. Catheter-Directed Administration
        13. Hospitals
        14. Specialty Clinics
        15. Ambulatory Surgical Centers
        16. Other End Users
Report Details
−
200+ Trusted Partners
LG Electronics AMCAD Engineering KOBE STEEL LTD. Hindustan National Glass & Industries Limited Voith Group International Paper Hansol Paper Whirlpool Corporation Sony Samsung Electronics Qualcomm Google Fiserv Veto-Pharma Nippon Becton Dickinson Merck Argon Medical Devices Abbott Ajinomoto Denon Doosan Meiji Seika Kaisha Ltd LG Chemicals LCY chemical group Bayer Airrane BASF Toyota Industries Nissan Motors Neenah Mitsubishi Hyundai Motor Company Honda CRP Industries Inc pewag LGE Panasonic Lubrizol Corporation Leonardo Johnson & Johnson HB Fuller MITSUBISHI CHEMICAL Hyundai Mobis Amazon
Download Free Sample
Reach out to us
+1 646 905 0080 (U.S.)
+44 203 695 0070 (U.K.)
sales@straitsresearch.com

We are featured on:

Straits Research
Address:
105, Panchshil The Golden Bell,
Koregaon Park Annexe, Mundhwa,
Pune, Maharashtra 411036
Contact Us:
+1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)

sales@straitsresearch.com

Quick Links
Help
Verified. Protected. Secure.
Duns
DMCA.com Protection Status
lets-encrypt
Secure Payments:
Secure Payments
Follow Us:
www.straitsresearch.com © Copyright . All rights Reserved.